PCV13 - Cost Effective Analysis Of Pharmaceutical Care In Management Of Patients With Stage Iii Hypertension: An Indian Pharmacists Experience

Abstract

To calculate and compare cost effectiveness in hypertensive patients between intervention and usual care group in Stage III uncontrollable hypertension. The present study was a prospective, randomized, comparative study in 1525 patients of stage III hypertension for 24 months. Patients were randomly divided into two groups. Intervention group patients were provided self-care education through a structured training session over 6 month period. Usual care group received usual care provided by the hospital and pharmacists. The economic evaluation on pharmaceutical care was based on patients perspective. The impact of the interventions on QoL was estimated by using the MINICHAL questionnaire. The primary outcomes were incremental cost-utility ratio and net monetary benefit. The data of the present study sowed an incremental cost due to periodic monitoring cost INR 2245 ($33.59) with 0.17 quality adjusted life year (QALY) gained. The present study also showed an incremental utility ratio INR 17,960 ($268.78) per QALY gained. In the cost-effectiveness acceptability curve, the probability that PC was more cost-effective than UCG was 90% at the INR 56,125 ($840) per QALY gained threshold and 66% at the INR 17,960 ($268.78) per QALY gained threshold. The PC was not very cost-effective among patients with stage III uncontrollable hypertension at the INR 17,960 ($268.78) per QALY gained threshold. However, there are considerable limitations in this study.